Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Odaka, Haruki ^a,b   Numakawa, Tadahiro ^a,c   Adachi, Naoki ^a,c   Ooshima, Yoshiko ^a   Nakajima, Shingo ^a,c   Katanuma, Yusuke ^a,b   Inoue, Takafumi ^b   Kunugi, Hiroshi ^a,c  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CABERGOLINE; CALCIUM CHANNEL L TYPE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EXCITATORY AMINO ACID TRANSPORTER 3; GLUTAMIC ACID; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SPIPERONE; DOPAMINE 2 RECEPTOR; ERGOLINE DERIVATIVE; GLUTAMATE TRANSPORTER; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUROPROTECTIVE AGENT; NEUROTOXIN; STRESS ACTIVATED PROTEIN KINASE;

AMINO ACID BRAIN LEVEL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BIOLOGICAL MODEL; BRAIN CORTEX; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NERVE CELL; PATHOLOGY; TIME; TOXICITY; UPREGULATION; WISTAR RAT;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; ERGOLINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUTAMIC ACID; HYDROGEN PEROXIDE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS, WISTAR; RECEPTORS, DOPAMINE D2; TIME FACTORS; UP-REGULATION;

EID: 84902593610     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099271     Document Type: Article

References (51)

1. Kvernmo T, Hartter S, Burger E. (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28: 1065-1078. (Pubitemid 44374749)
2. Baas HK, Schueler P. (2001) Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 46: 18-23. (Pubitemid 34008779)
3. Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, et al. (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev 1: 33.
4. Kalampokas T, Creatsas G, Kalampokas E. (2013) Cabergoline as treatment of ovarian hyperstimulation syndrome: a review. Gynecol Endocrinol 29: 98-100.
5. Feelders RA, Hofland LJ. (2013) Medical treatment of Cushing's disease. J Clin Endocrinol Metab 98: 425-438.
6. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, et al. (2011) Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev 16(3): CD006009.
7. Curran MP, Perry CM. (2004) Cabergoline : a review of its use in the treatment of Parkinson's disease. Drugs 64 (18): 2125-2141. (Pubitemid 39294733)
8. Pradeep H, Diya JB, Shashikumar S, Rajanikant GK. (2012) Oxidative stress - assassin behind the ischemic stroke. Folia Neuropathol 50 (3): 219-30.
9. Feng Y, Wang X. (2012) Antioxidant therapies for Alzheimer's disease. Oxid Med Cell Longev 2012 (2012): 472932.
10. Johri A, Beal MF. (2012) Antioxidants in Huntington's disease. Biochim Biophys Acta 1822 (5): 664-674.
11. Barber SC, Shaw PJ. (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48 (5): 629-641.
12. Hauser DN, Hastings TG. (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis 51: 35-42.
13. Kitamura Y, Taniguchi T, Shimohama S, Akaike A, Nomura Y. (2003) Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists. Neurochem Res 28 (7): 1035-40. (Pubitemid 36576200)
14. Yoshioka M, Tanaka Ki, Miyazaki I, Fujita N, Higashi Y, et al. (2002) The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci Res 43 (3): 259-267.
15. Miglio G, Varsaldi F, Francioli E, Battaglia A, Canonico PL, et al. (2004) Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. Eur J Pharmacol 489 (3): 157-165. (Pubitemid 38496224)
16. Chau KY, Korlipara LV, Cooper JM, Schapira AH. (2009) Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors. J Neurol Sci 278 (1-2): 44-53.
17. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, et al. (1998) Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 44 (1):110-119. (Pubitemid 28323660)
18. Lombardi G, Varsaldi F, Miglio G, Papini MG, Battaglia A, et al. Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. Eur J Pharmacol 457 (2-3): 95-98.
19. Tanaka K, Miyazaki I, Fujita N, Haque ME, Asanuma M, et al. (2001) Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist. Neurochem Res 26 (1): 31-36. (Pubitemid 32428810)
20. Jackson DM, Westlind-Danielsson A. (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64 (2): 291-370. (Pubitemid 124003168)
21. Chiba S, Numakawa T, Ninomiya M, Yoon HS, Kunugi H. (2010) Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling. Psychopharmacology (Berl) 211 (3): 291-301.
22. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H. (2013) Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 239: 157-172.
23. Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, et al. (2009) Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci U S A 106 (2): 647-652.
24. Leysen JE. (2004) 5-HT2 receptors. Curr Drug Targets CNS Neurol Disord 3 (1): 11-26.
25. Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, et al. (1997) Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 76 (2): 323-329. (Pubitemid 27008463)
26. Cagnol S, Chambard JC. (2010) ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277 (1): 2-21.
27. Schroeter H, Boyd C, Spencer JP, Williams RJ, Cadenas E, et al. (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol Aging 23 (5): 861-880. (Pubitemid 35217712)
28. Wang X, Martindale JL, Liu Y, Holbrook NJ. (1998) The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J 333 (Pt 2): 291-300. (Pubitemid 28379529)
29. Mailly F, Marin P, Israel M, Glowinski J, Premont J. (1999) Increase in external glutamate and NMDA receptor activation contribute to H2O2-induced neuronal apoptosis. J Neurochem 73 (3): 1181-1188. (Pubitemid 29395477)
30. Lee Y, Aono M, Laskowitz D, Warner DS, Pearlstein RD. (2004) Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity. Neurochem Int 44 (2): 107-118. (Pubitemid 37101387)
31. Choi DW. (1995) Calcium still center-stage in hypoxic-ischemic neuronal death. Trends Neurosci. 18(2): 58-60.
32. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, et al. (1994) Localization of neuronal and glial glutamate transporters. Neuron 13 (3): 713-725. (Pubitemid 24300175)
33. Guillet B, Lortet S, Masmejean F, Samuel D, Nieoullon A, et al. (2002) Developmental expression and activity of high affinity glutamate transporters in rat cortical primary cultures. Neurochem Int 40 (7): 661-671. (Pubitemid 34246245)
34. Himi T, Ikeda M, Yasuhara T, Nishida M, Morita I. (2003) Role of neuronal glutamate transporter in the cysteine uptake and intracellular glutathione levels in cultured cortical neurons. J Neural Transm 110 (12): 1337-1348. (Pubitemid 38041341)
35. Johnson GL, Lapadat R. (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (5600): 1911-1912. (Pubitemid 35425238)
36. Irving EA, Bamford M. (2002) Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 22 (6): 631-647. (Pubitemid 34596455)
37. Wang W, Hou XY, Gao C, Liu Y, Zong YY, et al. (2003) Regulation of c-Jun N-terminal kinase activation in hydrogen peroxide induced neurotoxicity. J Neurocytol 32 (2): 143-151. (Pubitemid 38019306)
38. Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, et al. (2005) Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 12 (10): 1329-1343. (Pubitemid 41486103)
39. Islam O, Loo TX, Heese K. (2009) Brain-derived neurotrophic factor (BDNF) has proliferative effects on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res 6 (1): 42-53.
40. Lim JY, Park SI, Oh JH, Kim SM, Jeong CH, et al. (2008) Brain-derived neurotrophic factor stimulates the neural differentiation of human umbilical cord blood-derived mesenchymal stem cells and survival of differentiated cells through MAPK/ERK and PI3K/Akt-dependent signaling pathways. J Neurosci Res 86 (10): 2168-2178.
41. Atwal JK, Massie B, Miller FD, Kaplan DR. (2000) The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. Neuron 27 (2): 265-277.
42. Zhuang S, Yan Y, Daubert RA, Han J, Schnellmann RG. (2007) ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol 292 (1): F440-F447. (Pubitemid 46105282)
43. Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, et al. (2000) Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275 (16): 12200-12206. (Pubitemid 30237798)
44. Crossthwaite AJ, Hasan S, Williams RJ. (2002) Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J Neurochem 80 (1): 24-35. (Pubitemid 34614574)
45. Kaneko T, Fujiyama F. (2002) Complementary distribution of vesicular glutamate transporters in the central nervous system. Neurosci Res 42 (4): 243-250. (Pubitemid 34414984)
46. Schinder AF, Olson EC, Spitzer NC, Montal M. (1996) Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16(19): 6125-6133. (Pubitemid 26313988)
47. Tian X, Gotoh T, Tsuji K, Lo EH, Huang S, et al. (2004) Developmentally regulated role for Ras-GRFs in coupling NMDA glutamate receptors to Ras, Erk and CREB. EMBO J 23 (7): 1567-1575. (Pubitemid 38579517)
48. Samanta S, Perkinton MS, Morgan M, Williams RJ. (1998) Hydrogen peroxide enhances signal-responsive arachidonic acid release from neurons: role of mitogen-activated protein kinase. J Neurochem 70(5): 2082-2090. (Pubitemid 28207832)
49. Resink A, Villa M, Boer GJ, Mohler H, Balazs R. (1995) Agonist-induced down-regulation of NMDA receptors in cerebellar granule cells in culture. Eur J Neurosci 7(8): 1700-1706.
50. Yang L, Li XB, Yang Q, Zhang K, Zhang N, et al. (2013) The neuroprotective effect of praeruptorin C against NMDA-induced apoptosis through down-regulating of GluN2B-containing NMDA receptors. Toxicol In Vitro 27 (2): 908-914.
51. Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, et al. (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16(3): 675-686. (Pubitemid 26103145)